Milsaperidone (VHX-896) vs Paliperidone palmitate (Erzofri)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Paliperidone palmitate (Erzofri)

Marketed by Luye Pharma Group

Approved in Schizophreniasmall molecule
Partial signal

NCT03751488 · Phase 1 · completed

This randomized, open-label, single-dose Phase 1 study in 48 patients with schizophrenia compared the pharmacokinetics of LY03010 (this product, at 117, 156 and 351 mg) with INVEGA SUSTENNA 156 mg. It measures drug exposure, not clinical efficacy, and no results have been posted.

Next expected readout: December 2027 · NCT07927946 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Paliperidone palmitate (Erzofri)
PANSS total, change—Not reported—Not reported
CGI-S, change—Not reported—Not reported
PANSS response—Not reported—Not reported
PSP, change—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Erzofri)
—Not reported

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Erzofri)
—Not reported

PANSS response

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Erzofri)
—Not reported

PSP, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Erzofri)
—Not reported

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Erzofri)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Paliperidone palmitate (Erzofri): no structured comparison results are available for Schizophrenia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone palmitate (Erzofri)'s landscape